
Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Description
Osteoarthritis Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Drugs In Development, 2022, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.
Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 39, 27, 2, 5, 80, 23 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2, 9 and 7 molecules, respectively.
Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoarthritis - Drugs In Development, 2022, provides an overview of the Osteoarthritis (Musculoskeletal Disorders) pipeline landscape.
Osteoarthritis (OA) is one of the most common forms of arthritis. It is a chronic condition in which the cartilage breaks down. Symptoms of osteoarthritis include sore or stiff joints, pain that is worse after activity, bone spurs and grating sensation. Risk factors include older age, joint injuries and obesity. Treatment includes surgery, medications like non-steroidal anti-inflammatory drugs (NSAIDs) and exercise.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoarthritis - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Osteoarthritis (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoarthritis (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoarthritis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 13, 39, 27, 2, 5, 80, 23 and 2 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 2, 9 and 7 molecules, respectively.
Osteoarthritis (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoarthritis (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoarthritis (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoarthritis (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoarthritis (Musculoskeletal Disorders)
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoarthritis (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoarthritis (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
401 Pages
- Introduction
- Global Markets Direct Report Coverage
- Osteoarthritis – Overview
- Osteoarthritis – Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Osteoarthritis – Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Osteoarthritis – Companies Involved in Therapeutics Development
- 20MED Therapeutics BV
- 4P-Pharma SAS
- Abiogen Pharma SpA
- Achelios Therapeutics Inc
- Aclaris Therapeutics Inc
- Adare Pharma Solutions
- AfaSci Inc
- Ageless Biotech Inc
- Akaal Pharma Pty Ltd
- Akan Biosciences LLC
- AKL Research and Development Ltd
- Algomedix Inc
- Amgen Inc
- Amplicore Inc
- Amzell BV
- Aprogen Inc
- AskAt Inc
- Asta Pharmaceuticals Co Ltd
- Atlanthera
- Aurealis Pharma AG
- Axsome Therapeutics Inc
- Bioiberica SAU
- BioIntegrate Inc
- BioNet Pharma GmbH
- Bioorg3.14 LLC
- Biosplice Therapeutics Inc
- BioStem Technologies Inc
- Bioventus Inc
- BRIM Biotechnology Inc
- Buzzz Pharmaceuticals Ltd
- Caliway Biopharmaceutics Co Ltd
- CAR-T (Shanghai) Biotechnology Co Ltd
- Cartesian Therapeutics Inc
- CarthroniX Inc
- Cartilagen Inc
- Causeway Therapeutics Ltd
- Cellatoz Therapeutics Inc
- Cellics Therapeutics Inc
- CELLnLIFE Inc
- Cells for Cells SA
- CellTex Therapeutics Corp
- Cellular Biomedicine Group Inc
- Chondrogenix Ltd
- Cmxtwenty
- Cocoon Biotech, Inc.
- Corestem Inc
- CrystalGenomics Inc
- Cynata Therapeutics Ltd
- Cytonics Corp
- Cytopeutics Pte Ltd
- Daewoong Pharmaceutical Co Ltd
- Dianomi Therapeutics Inc
- DNX Biopharmaceuticals Inc
- Dongkook Pharmaceutical Co Ltd
- Eli Lilly and Co
- Ensol Biosciences Inc
- Enveric Biosciences Inc
- Epione Therapeutics BV
- Eternity Bioscience Inc
- Evgen Pharma Plc
- Exostemtech Co Ltd
- Flexion Therapeutics Inc
- Genascence Corp
- Genequine Biotherapeutics GmbH
- General Regeneratives Shanghai Ltd
- General Therapeutics Inc
- GlaxoSmithKline Plc
- GPN Therapeutics Inc
- Guangzhou Saliai Stemcell Science and Technology Co Ltd
- Gwoxi Stem Cell Applied Technology Co Ltd
- Haplnscience Inc
- Hisamitsu Pharmaceutical Co Inc
- Histogen Inc
- Hope Biosciences LLC
- Huaxia Source Cell Engineering Group Co Ltd
- iCELL Biotechnology Co Ltd
- ICM Co Ltd
- Immetas Therapeutics Inc
- ImmuneCyte Inc
- ImmunoForge Co Ltd
- Inception Therapeutics Inc
- International Stem Cell Corp
- Johnson & Johnson
- Juniper Biologics Pte Ltd
- Juvena Therapeutics Inc
- Kaken Pharmaceutical Co Ltd
- Kangstem Biotech Co Ltd
- Kolon TissueGene Inc
- Kukje Pharmaceutical Industry Co Ltd
- Levolta Pharmaceuticals Inc
- LG Chem Ltd
- Likarda LLC
- Link Biologics Ltd
- Link Health Group
- Lubris Biopharma
- Luye Pharma Group Ltd
- Magellan Biologicals Pty Ltd
- MDimune Inc
- Mecox Cure Med Co Ltd
- Medicrinia Co Ltd
- MediPost Co Ltd
- Medivir AB
- MeiraGTx Holdings Plc
- Meluha Life Sciences Sdn Bhd
- Merck KGaA
- Meridigen Biotech Co Ltd
- Mesoblast Ltd
- MetrioPharm AG
- MiMedx Group Inc
- Mor Research Applications Ltd
- Nanode Therapeutics Inc
- NeuroBo Pharmaceuticals Inc
- New York R&D Center for Translational Medicine and Therapeutics Inc
- Nexbiome Therapeutics
- Nordic Bioscience AS
- Novartis AG
- Novo Nordisk AS
- Orbsen Therapeutics Ltd
- Organicell Regenerative Medicine Inc
- Organogenesis Holdings Inc
- OrthoTrophix Inc
- Oxacell AG
- Paradigm Biopharmaceuticals Ltd
- Paras Biopharmaceuticals Finland Oy
- Parnia Stem Cell Knowledge-Based Co
- Peptinov SAS
- Personalized Stem Cells Inc
- PersonGen BioTherapeutics (Suzhou) Co Ltd
- Pfizer Inc
- PhytoHealth Corp
- Plakous Therapeutics Inc
- PlateletBio
- PMG PHARM Co Ltd
- PrimeGen Global Inc
- PrimRNA Inc
- Progenitor Therapeutics Ltd
- ProteoThera Inc
- Regeneus Ltd
- Regenosine Inc
- Regulaxis SAS
- Remedium Bio Inc
- ReqMed Co Ltd
- Ribomic Inc
- Rottapharm Biotech Srl
- Runjia (Suzhou) Pharmaceutical Technology Co Ltd
- Sclnow Biotechnology Co Ltd
- Seikagaku Corp
- Serene LLC
- Shandong Boan Biotechnology Co Ltd
- Shionogi & Co Ltd
- Simcere Pharmaceutical Group Ltd
- SL Bigen Co Ltd
- Steminent Biotherapeutics Inc
- Stempeutics Research Pvt Ltd
- Synartro AB
- Synerkine Pharma BV
- Synokem Pharmaceuticals Ltd
- Taiwan Bio Therapeutics Co Ltd
- Techfields Pharma Co Ltd
- TheraBioPharma Inc
- Traverse Biosciences Inc
- Tremeau Pharmaceuticals Inc
- Trialspark Inc
- Turn Biotechnologies Inc
- Unicocell Biomed Co Ltd
- Vitro Diagnostics Inc
- WEX Pharmaceuticals Inc
- WNT Scientific LLC
- Xalud Therapeutics Inc
- Xintela AB
- Yooyoung Pharm Co Ltd
- Zhejiang Yatai Pharmaceutical Co Ltd
- Zimmer Biomet Holdings Inc
- Osteoarthritis – Drug Profiles
- (apocynin + paeonol) – Drug Profile
- (clodronate disodium + hyaluronic acid) – Drug Profile
- (meloxicam + esomeprazole) – Drug Profile
- (methylprednisolone + zoledronic acid) – Drug Profile
- (polmacoxib + tramadol) – Drug Profile
- AAT-008 – Drug Profile
- AFA-281 – Drug Profile
- AK-1830 – Drug Profile
- AKP-11 – Drug Profile
- AlloJoin – Drug Profile
- AM-1101 – Drug Profile
- AmnioFix – Drug Profile
- AN-04 – Drug Profile
- Antibody for Osteoarthritis – Drug Profile
- Antibody to Inhibit TGF-Beta 1 for Osteoarthritis – Drug Profile
- Antisense Oligonucleotide for Osteoarthritis – Drug Profile
- Antisense RNAi Oligonucleotide to Inhibit MicroRNA-181a for Chondrosarcoma, Rheumatoid Arthritis and Osteoarthritis – Drug Profile
- Antisense RNAi Oligonucleotides to Inhibit MMP-13 for Osteoarthritis – Drug Profile
- AP-20 – Drug Profile
- ArthriC – Drug Profile
- ARTI-02 – Drug Profile
- AS-001 – Drug Profile
- bermekimab – Drug Profile
- BG-137 – Drug Profile
- Biologic for Knee Osteoarthritis – Drug Profile
- Biologics for Knee Osteoarthritis – Drug Profile
- Biologics for Osteoarthritis – Drug Profile
- BN-02 – Drug Profile
- BRH-1101 – Drug Profile
- BRM-521 – Drug Profile
- BSEM-004 – Drug Profile
- canakinumab – Drug Profile
- Cartistem – Drug Profile
- CBO-012 SR – Drug Profile
- celecoxib – Drug Profile
- Cell Therapy for Autoimmune Disorders, Cardiovascular Disorders, CNS Disorders, Infectious Disease, Musculoskeletal Disorders and Oncology – Drug Profile
- Cell Therapy for Knee Arthritis – Drug Profile
- Cell Therapy for Osteoarthritis – Drug Profile
- CG-001 – Drug Profile
- Chondrochymal – Drug Profile
- Chondrogen – Drug Profile
- Chondrokin – Drug Profile
- Chondrosome – Drug Profile
- clodronate disodium – Drug Profile
- CLV-100 – Drug Profile
- CLZ-1001 – Drug Profile
- CMX-020 – Drug Profile
- CR-8357 – Drug Profile
- CS-30MS02 – Drug Profile
- CTI-156 – Drug Profile
- CUCPT-8m – Drug Profile
- curcumin glucuronide – Drug Profile
- CWT-002 – Drug Profile
- CX-011 – Drug Profile
- CX-159 – Drug Profile
- CYP-002 – Drug Profile
- CYP-004 – Drug Profile
- CYT-108 – Drug Profile
- denosumab – Drug Profile
- Descartes-41 – Drug Profile
- diclofenac – Drug Profile
- diclofenac etalhyaluronate sodium SR – Drug Profile
- diclofenac sodium – Drug Profile
- DKM-412 – Drug Profile
- DKM-420 – Drug Profile
- DNX-314 – Drug Profile
- Drugs to Agonize ADORA2A for Osteoarthritis – Drug Profile
- Drugs to Modulate PPAR-Delta for Metabolic and Musculoskeletal Disorders – Drug Profile
- DTX-010 – Drug Profile
- DWP-820S003 – Drug Profile
- ECF-843 – Drug Profile
- Elixcyte – Drug Profile
- Engedi-1000 – Drug Profile
- EV-104a – Drug Profile
- FAX-051T – Drug Profile
- Furestem-OA – Drug Profile
- Fusion Protein to Target Galectin-3 for Bacterial Infections, Osteoarthritis and Periodontal Disease – Drug Profile
- Fusion Proteins for Osteoarthritis – Drug Profile
- FX-201 – Drug Profile
- G-001 – Drug Profile
- gemcabene – Drug Profile
- Gene Therapy for Osteoarthritis – Drug Profile
- GLPG-0555 – Drug Profile
- GNSC-001 – Drug Profile
- GQ-303 – Drug Profile
- GR-008 – Drug Profile
- GXCPC-1 – Drug Profile
- HS-101 – Drug Profile
- HST-003 – Drug Profile
- ICM-203O – Drug Profile
- iguratimod – Drug Profile
- IMC-2013 – Drug Profile
- Inulin Polysulfate – Drug Profile
- ITIDMOAD-102 – Drug Profile
- JointStem – Drug Profile
- KA-34 – Drug Profile
- KAG-308 – Drug Profile
- KBP-056 – Drug Profile
- ketoprofen – Drug Profile
- KJ-16002 – Drug Profile
- LG-00034053 – Drug Profile
- LH-021 – Drug Profile
- LIK-09 – Drug Profile
- Link_TSG6 – Drug Profile
- liraglutide – Drug Profile
- LNA-043 – Drug Profile
- lorecivivint – Drug Profile
- LR-19024 – Drug Profile
- LR-19025 – Drug Profile
- LRX-712 – Drug Profile
- LY-03012 – Drug Profile
- M-002 – Drug Profile
- M-1673 – Drug Profile
- M-6495 – Drug Profile
- MAG-200 – Drug Profile
- MBIGF-1 – Drug Profile
- meloxicam ER – Drug Profile
- MIV-711 – Drug Profile
- MOG-001 – Drug Profile
- MOG-002 – Drug Profile
- Monoclonal Antibodies for Osteoarthritis – Drug Profile
- Monoclonal Antibody to Target NGF beta in Chronic Back Pain, Cancer Pain and Osteoarthritis – Drug Profile
- MP-1032 – Drug Profile
- MPC-75IA – Drug Profile
- NStride APS – Drug Profile
- OA-SYS – Drug Profile
- Oligonucleotide for Knee Osteoarthritis – Drug Profile
- Oligonucleotides for Osteoarthritis – Drug Profile
- Osteoarthritis Treatment – Drug Profile
- Oxaceprol SR – Drug Profile
- Ozempic – Drug Profile
- PBOA-5010 – Drug Profile
- pentosan polysulfate sodium – Drug Profile
- Peptide for Osteoarthritis – Drug Profile
- PF-1803 – Drug Profile
- PGUSOA-1 – Drug Profile
- PHDC-02 – Drug Profile
- PK-101 – Drug Profile
- Plartistem – Drug Profile
- PPV-06 – Drug Profile
- PRO-1 – Drug Profile
- Progenza – Drug Profile
- PROTEGO-PD – Drug Profile
- Protein to Agonize NRP2 and NRP3 for Osteoarthritis – Drug Profile
- Proteins for Rheumatoid Arthritis and Osteoarthritis – Drug Profile
- PSC-01 – Drug Profile
- PTP-001 – Drug Profile
- RBM-010 – Drug Profile
- Recombinant Protein to Agonize CCR9 for Osteoarthritis – Drug Profile
- redasemtide trifluoroacetate – Drug Profile
- Reg-O3 – Drug Profile
- ReJoin – Drug Profile
- ReNu – Drug Profile
- RHH-466 – Drug Profile
- RMD-1101 – Drug Profile
- rofecoxib – Drug Profile
- RP-901 – Drug Profile
- SFX-01 – Drug Profile
- SK-01 – Drug Profile
- SLBM-127 – Drug Profile
- Small Molecule for Immunology and Musculoskeletal Disorders – Drug Profile
- Small Molecule for Musculoskeletal Disorders and Rheumatoid Arthritis – Drug Profile
- Small Molecule for Osteoarthritis – Drug Profile
- Small Molecule to Antagonize TRPA1 for Pain and Respiratory Disorders – Drug Profile
- Small Molecules for Fibrosis and Osteoarthritis – Drug Profile
- Small Molecules for Metabolic and Musculoskeletal Disorders – Drug Profile
- Small Molecules for Musculoskeletal and Metabolic Disorders – Drug Profile
- Small Molecules for Osteoarthritis – Drug Profile
- Small Molecules to Inhibit ADAMTS4 and ADAMTS5 for Osteoarthritis – Drug Profile
- Small Molecules to Inhibit iNOS for Osteoarthritis – Drug Profile
- Small Molecules to Inhibit Matriptase for Osteoarthritis – Drug Profile
- SMUPIA-01 – Drug Profile
- sprifermin – Drug Profile
- Stem Cell Therapy for Alzheimer's Disease, Osteoarthritis and Rheumatoid Arthritis – Drug Profile
- Stem Cell Therapy for Central Nervous System, Infectious Disease, Oncology, Cardiovascular, Genetic Disorders, Women's Health and Musculoskeletal Disorders – Drug Profile
- Stem Cell Therapy for Coronavirus Disease 2019 (COVID-19), Genetic Disorders, Osteoarthritis, Unspecified Musculoskeletal Disorders, Neurological disorders, Autoimmune disorders, Kidney Disease and Inflammation – Drug Profile
- Stem Cell Therapy for Knee Osteoarthritis – Drug Profile
- Stem Cell Therapy for Knee Osteoarthritis, Depression, Type 2 Diabetes and Coronavirus Disease 2019 (COVID-19) – Drug Profile
- Stem cell Therapy for Osteoarthritis – Drug Profile
- Stem Cell Therapy for Osteoarthritis and Rheumatoid Arthritis – Drug Profile
- Stem Cell Therapy to Target vIL-10 for Osteoarthritis and Rheumatoid Arthritis – Drug Profile
- Stemchymal – Drug Profile
- StemGEL – Drug Profile
- Stempeucel – Drug Profile
- StroMel – Drug Profile
- SYN-321 – Drug Profile
- TAA-08 – Drug Profile
- Tetrodotoxin – Drug Profile
- Tin-117m Colloid – Drug Profile
- tonogenchoncel-L – Drug Profile
- TPX-100 – Drug Profile
- TRBN-0224 – Drug Profile
- triamcinolone acetonide – Drug Profile
- TRN-003 – Drug Profile
- UMC-1190605 – Drug Profile
- X-0002 – Drug Profile
- XSTEM – Drug Profile
- XT-150 – Drug Profile
- YYD-302 – Drug Profile
- Zofin – Drug Profile
- zunsemetinib – Drug Profile
- Osteoarthritis – Dormant Projects
- Osteoarthritis – Discontinued Products
- Osteoarthritis – Product Development Milestones
- Featured News & Press Releases
- Apr 13, 2022: FDA grants Fast Track Designation for Paradigm Biopharmaceuticals phase III osteoarthritis program
- Apr 08, 2022: TPX-100: OrthoTrophix presents new data suggesting joint bone shape as a possible surrogate marker for virtual joint replacement in knee osteoarthritis
- Mar 17, 2022: Paradigm Biopharmaceuticals initiates a phase 3 clinical trial in knee osteoarthritis across the U.S
- Mar 17, 2022: Paradigm has received regulatory and ethics approvals for the PARA_OA_002 clinical trial in the UK.
- Mar 14, 2022: Medipost begins administration of knee osteoarthritis drug in P2 trial
- Mar 03, 2022: 4P-Pharma and QuantHealth join forces to conduct AI-based in-Silico clinical trial simulations
- Feb 17, 2022: Synartro granted European patent
- Feb 08, 2022: Enveric Biosciences announces successful synthesis and filing of provisional patent for EV-104a – Cannabinoid + Celecoxib Conjugate
- Jan 13, 2022: First subjects randomised dosed in PARA_0A_002 phase 3 study in Australia
- Jan 12, 2022: Paradigm presentation at the 40th Annual J.P. Morgan Healthcare Conference
- Dec 28, 2021: Kolon TissueGene resumes TG-C phase III studies in the U.S.
- Dec 13, 2021: FDA approves XBiotech’s IND in rheumatology
- Dec 03, 2021: Kolon TissueGene to expand indications for TG-C
- Nov 01, 2021: Two new studies demonstrate in vitro bioactivity potential of micronized dehydrated human amnion chorion membrane (mdHACM) to prevent pathological processes underlying osteoarthritis (OA) and tendinopathy
- Sep 21, 2021: TPX-100: OrthoTrophix published a new research article demonstrating disease modification in knee osteoarthritis
- Appendix
- Methodology
- Coverage
- Secondary Research
- Primary Research
- Expert Panel Validation
- Contact Us
- Disclaimer
- List of Tables
- Table 1: Number of Products under Development for Osteoarthritis, 2022
- Table 2: Number of Products under Development by Companies, 2022
- Table 3: Number of Products under Development by Companies, 2022 (Contd..1)
- Table 4: Number of Products under Development by Companies, 2022 (Contd..2)
- Table 5: Number of Products under Development by Companies, 2022 (Contd..3)
- Table 6: Number of Products under Development by Companies, 2022 (Contd..4)
- Table 7: Number of Products under Development by Companies, 2022 (Contd..5)
- Table 8: Number of Products under Development by Companies, 2022 (Contd..6)
- Table 9: Number of Products under Development by Companies, 2022 (Contd..7)
- Table 10: Number of Products under Development by Companies, 2022 (Contd..8)
- Table 11: Number of Products under Development by Universities/Institutes, 2022
- Table 12: Products under Development by Companies, 2022
- Table 13: Products under Development by Companies, 2022 (Contd..1)
- Table 14: Products under Development by Companies, 2022 (Contd..2)
- Table 15: Products under Development by Companies, 2022 (Contd..3)
- Table 16: Products under Development by Companies, 2022 (Contd..4)
- Table 17: Products under Development by Companies, 2022 (Contd..5)
- Table 18: Products under Development by Companies, 2022 (Contd..6)
- Table 19: Products under Development by Companies, 2022 (Contd..7)
- Table 20: Products under Development by Companies, 2022 (Contd..8)
- Table 21: Products under Development by Companies, 2022 (Contd..9)
- Table 22: Products under Development by Companies, 2022 (Contd..10)
- Table 23: Products under Development by Universities/Institutes, 2022
- Table 24: Products under Development by Universities/Institutes, 2022 (Contd..1)
- Table 25: Number of Products by Stage and Target, 2022
- Table 26: Number of Products by Stage and Target, 2022 (Contd..1)
- Table 27: Number of Products by Stage and Target, 2022 (Contd..2)
- Table 28: Number of Products by Stage and Mechanism of Action, 2022
- Table 29: Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
- Table 30: Number of Products by Stage and Mechanism of Action, 2022 (Contd..2)
- Table 31: Number of Products by Stage and Route of Administration, 2022
- Table 32: Number of Products by Stage and Molecule Type, 2022
- Table 33: Osteoarthritis – Pipeline by 20MED Therapeutics BV, 2022
- Table 34: Osteoarthritis – Pipeline by 4P-Pharma SAS, 2022
- Table 35: Osteoarthritis – Pipeline by Abiogen Pharma SpA, 2022
- Table 36: Osteoarthritis – Pipeline by Achelios Therapeutics Inc, 2022
- Table 37: Osteoarthritis – Pipeline by Aclaris Therapeutics Inc, 2022
- Table 38: Osteoarthritis – Pipeline by Adare Pharma Solutions, 2022
- Table 39: Osteoarthritis – Pipeline by AfaSci Inc, 2022
- Table 40: Osteoarthritis – Pipeline by Ageless Biotech Inc, 2022
- Table 41: Osteoarthritis – Pipeline by Akaal Pharma Pty Ltd, 2022
- Table 42: Osteoarthritis – Pipeline by Akan Biosciences LLC, 2022
- Table 43: Osteoarthritis – Pipeline by AKL Research and Development Ltd, 2022
- Table 44: Osteoarthritis – Pipeline by Algomedix Inc, 2022
- Table 45: Osteoarthritis – Pipeline by Amgen Inc, 2022
- Table 46: Osteoarthritis – Pipeline by Amplicore Inc, 2022
- Table 47: Osteoarthritis – Pipeline by Amzell BV, 2022
- Table 48: Osteoarthritis – Pipeline by Aprogen Inc, 2022
- Table 49: Osteoarthritis – Pipeline by AskAt Inc, 2022
- Table 50: Osteoarthritis – Pipeline by Asta Pharmaceuticals Co Ltd, 2022
- Table 51: Osteoarthritis – Pipeline by Atlanthera, 2022
- Table 52: Osteoarthritis – Pipeline by Aurealis Pharma AG, 2022
- Table 53: Osteoarthritis – Pipeline by Axsome Therapeutics Inc, 2022
- Table 54: Osteoarthritis – Pipeline by Bioiberica SAU, 2022
- Table 55: Osteoarthritis – Pipeline by BioIntegrate Inc, 2022
- Table 56: Osteoarthritis – Pipeline by BioNet Pharma GmbH, 2022
- Table 57: Osteoarthritis – Pipeline by Bioorg3.14 LLC, 2022
- Table 58: Osteoarthritis – Pipeline by Biosplice Therapeutics Inc, 2022
- Table 59: Osteoarthritis – Pipeline by BioStem Technologies Inc, 2022
- Table 60: Osteoarthritis – Pipeline by Bioventus Inc, 2022
- Table 61: Osteoarthritis – Pipeline by BRIM Biotechnology Inc, 2022
- Table 62: Osteoarthritis – Pipeline by Buzzz Pharmaceuticals Ltd, 2022
- Table 63: Osteoarthritis – Pipeline by Caliway Biopharmaceutics Co Ltd, 2022
- Table 64: Osteoarthritis – Pipeline by CAR-T (Shanghai) Biotechnology Co Ltd, 2022
- Table 65: Osteoarthritis – Pipeline by Cartesian Therapeutics Inc, 2022
- Table 66: Osteoarthritis – Pipeline by CarthroniX Inc, 2022
- Table 67: Osteoarthritis – Pipeline by Cartilagen Inc, 2022
- Table 68: Osteoarthritis – Pipeline by Causeway Therapeutics Ltd, 2022
- Table 69: Osteoarthritis – Pipeline by Cellatoz Therapeutics Inc, 2022
- Table 70: Osteoarthritis – Pipeline by Cellics Therapeutics Inc, 2022
- Table 71: Osteoarthritis – Pipeline by CELLnLIFE Inc, 2022
- Table 72: Osteoarthritis – Pipeline by Cells for Cells SA, 2022
- Table 73: Osteoarthritis – Pipeline by CellTex Therapeutics Corp, 2022
- Table 74: Osteoarthritis – Pipeline by Cellular Biomedicine Group Inc, 2022
- Table 75: Osteoarthritis – Pipeline by Chondrogenix Ltd, 2022
- Table 76: Osteoarthritis – Pipeline by Cmxtwenty, 2022
- Table 77: Osteoarthritis – Pipeline by Cocoon Biotech, Inc., 2022
- Table 78: Osteoarthritis – Pipeline by Corestem Inc, 2022
- Table 79: Osteoarthritis – Pipeline by CrystalGenomics Inc, 2022
- Table 80: Osteoarthritis – Pipeline by Cynata Therapeutics Ltd, 2022
- Table 81: Osteoarthritis – Pipeline by Cytonics Corp, 2022
- Table 82: Osteoarthritis – Pipeline by Cytopeutics Pte Ltd, 2022
- Table 83: Osteoarthritis – Pipeline by Daewoong Pharmaceutical Co Ltd, 2022
- Table 84: Osteoarthritis – Pipeline by Dianomi Therapeutics Inc, 2022
- Table 85: Osteoarthritis – Pipeline by DNX Biopharmaceuticals Inc, 2022
- Table 86: Osteoarthritis – Pipeline by Dongkook Pharmaceutical Co Ltd, 2022
- Table 87: Osteoarthritis – Pipeline by Eli Lilly and Co, 2022
- Table 88: Osteoarthritis – Pipeline by Ensol Biosciences Inc, 2022
- Table 89: Osteoarthritis – Pipeline by Enveric Biosciences Inc, 2022
- Table 90: Osteoarthritis – Pipeline by Epione Therapeutics BV, 2022
- Table 91: Osteoarthritis – Pipeline by Eternity Bioscience Inc, 2022
- Table 92: Osteoarthritis – Pipeline by Evgen Pharma Plc, 2022
- Table 93: Osteoarthritis – Pipeline by Exostemtech Co Ltd, 2022
- Table 94: Osteoarthritis – Pipeline by Flexion Therapeutics Inc, 2022
- Table 95: Osteoarthritis – Pipeline by Genascence Corp, 2022
- Table 96: Osteoarthritis – Pipeline by Genequine Biotherapeutics GmbH, 2022
- Table 97: Osteoarthritis – Pipeline by General Regeneratives Shanghai Ltd, 2022
- Table 98: Osteoarthritis – Pipeline by General Therapeutics Inc, 2022
- Table 99: Osteoarthritis – Pipeline by GlaxoSmithKline Plc, 2022
- Table 100: Osteoarthritis – Pipeline by GPN Therapeutics Inc, 2022
- Table 101: Osteoarthritis – Pipeline by Guangzhou Saliai Stemcell Science and Technology Co Ltd, 2022
- Table 102: Osteoarthritis – Pipeline by Gwoxi Stem Cell Applied Technology Co Ltd, 2022
- Table 103: Osteoarthritis – Pipeline by Haplnscience Inc, 2022
- Table 104: Osteoarthritis – Pipeline by Hisamitsu Pharmaceutical Co Inc, 2022
- Table 105: Osteoarthritis – Pipeline by Histogen Inc, 2022
- Table 106: Osteoarthritis – Pipeline by Hope Biosciences LLC, 2022
- Table 107: Osteoarthritis – Pipeline by Huaxia Source Cell Engineering Group Co Ltd, 2022
- Table 108: Osteoarthritis – Pipeline by iCELL Biotechnology Co Ltd, 2022
- Table 109: Osteoarthritis – Pipeline by ICM Co Ltd, 2022
- Table 110: Osteoarthritis – Pipeline by Immetas Therapeutics Inc, 2022
- Table 111: Osteoarthritis – Pipeline by ImmuneCyte Inc, 2022
- Table 112: Osteoarthritis – Pipeline by ImmunoForge Co Ltd, 2022
- Table 113: Osteoarthritis – Pipeline by Inception Therapeutics Inc, 2022
- Table 114: Osteoarthritis – Pipeline by International Stem Cell Corp, 2022
- Table 115: Osteoarthritis – Pipeline by Johnson & Johnson, 2022
- Table 116: Osteoarthritis – Pipeline by Juniper Biologics Pte Ltd, 2022
- Table 117: Osteoarthritis – Pipeline by Juvena Therapeutics Inc, 2022
- Table 118: Osteoarthritis – Pipeline by Kaken Pharmaceutical Co Ltd, 2022
- Table 119: Osteoarthritis – Pipeline by Kangstem Biotech Co Ltd, 2022
- Table 120: Osteoarthritis – Pipeline by Kolon TissueGene Inc, 2022
- Table 121: Osteoarthritis – Pipeline by Kukje Pharmaceutical Industry Co Ltd, 2022
- Table 122: Osteoarthritis – Pipeline by Levolta Pharmaceuticals Inc, 2022
- Table 123: Osteoarthritis – Pipeline by LG Chem Ltd, 2022
- Table 124: Osteoarthritis – Pipeline by Likarda LLC, 2022
- Table 125: Osteoarthritis – Pipeline by Link Biologics Ltd, 2022
- Table 126: Osteoarthritis – Pipeline by Link Health Group, 2022
- Table 127: Osteoarthritis – Pipeline by Lubris Biopharma, 2022
- Table 128: Osteoarthritis – Pipeline by Luye Pharma Group Ltd, 2022
- Table 129: Osteoarthritis – Pipeline by Magellan Biologicals Pty Ltd, 2022
- Table 130: Osteoarthritis – Pipeline by MDimune Inc, 2022
- Table 131: Osteoarthritis – Pipeline by Mecox Cure Med Co Ltd, 2022
- Table 132: Osteoarthritis – Pipeline by Medicrinia Co Ltd, 2022
- Table 133: Osteoarthritis – Pipeline by MediPost Co Ltd, 2022
- Table 134: Osteoarthritis – Pipeline by Medivir AB, 2022
- Table 135: Osteoarthritis – Pipeline by MeiraGTx Holdings Plc, 2022
- Table 136: Osteoarthritis – Pipeline by Meluha Life Sciences Sdn Bhd, 2022
- Table 137: Osteoarthritis – Pipeline by Merck KGaA, 2022
- Table 138: Osteoarthritis – Pipeline by Meridigen Biotech Co Ltd, 2022
- Table 139: Osteoarthritis – Pipeline by Mesoblast Ltd, 2022
- Table 140: Osteoarthritis – Pipeline by MetrioPharm AG, 2022
- Table 141: Osteoarthritis – Pipeline by MiMedx Group Inc, 2022
- Table 142: Osteoarthritis – Pipeline by Mor Research Applications Ltd, 2022
- Table 143: Osteoarthritis – Pipeline by Nanode Therapeutics Inc, 2022
- Table 144: Osteoarthritis – Pipeline by NeuroBo Pharmaceuticals Inc, 2022
- Table 145: Osteoarthritis – Pipeline by New York R&D Center for Translational Medicine and Therapeutics Inc, 2022
- Table 146: Osteoarthritis – Pipeline by Nexbiome Therapeutics, 2022
- Table 147: Osteoarthritis – Pipeline by Nordic Bioscience AS, 2022
- Table 148: Osteoarthritis – Pipeline by Novartis AG, 2022
- Table 149: Osteoarthritis – Pipeline by Novo Nordisk AS, 2022
- Table 150: Osteoarthritis – Pipeline by Orbsen Therapeutics Ltd, 2022
- Table 151: Osteoarthritis – Pipeline by Organicell Regenerative Medicine Inc, 2022
- Table 152: Osteoarthritis – Pipeline by Organogenesis Holdings Inc, 2022
- Table 153: Osteoarthritis – Pipeline by OrthoTrophix Inc, 2022
- Table 154: Osteoarthritis – Pipeline by Oxacell AG, 2022
- Table 155: Osteoarthritis – Pipeline by Paradigm Biopharmaceuticals Ltd, 2022
- Table 156: Osteoarthritis – Pipeline by Paras Biopharmaceuticals Finland Oy, 2022
- Table 157: Osteoarthritis – Pipeline by Parnia Stem Cell Knowledge-Based Co, 2022
- Table 158: Osteoarthritis – Pipeline by Peptinov SAS, 2022
- Table 159: Osteoarthritis – Pipeline by Personalized Stem Cells Inc, 2022
- Table 160: Osteoarthritis – Pipeline by PersonGen BioTherapeutics (Suzhou) Co Ltd, 2022
- Table 161: Osteoarthritis – Pipeline by Pfizer Inc, 2022
- Table 162: Osteoarthritis – Pipeline by PhytoHealth Corp, 2022
- Table 163: Osteoarthritis – Pipeline by Plakous Therapeutics Inc, 2022
- Table 164: Osteoarthritis – Pipeline by PlateletBio, 2022
- Table 165: Osteoarthritis – Pipeline by PMG PHARM Co Ltd, 2022
- Table 166: Osteoarthritis – Pipeline by PrimeGen Global Inc, 2022
- Table 167: Osteoarthritis – Pipeline by PrimRNA Inc, 2022
- Table 168: Osteoarthritis – Pipeline by Progenitor Therapeutics Ltd, 2022
- Table 169: Osteoarthritis – Pipeline by ProteoThera Inc, 2022
- Table 170: Osteoarthritis – Pipeline by Regeneus Ltd, 2022
- Table 171: Osteoarthritis – Pipeline by Regenosine Inc, 2022
- Table 172: Osteoarthritis – Pipeline by Regulaxis SAS, 2022
- Table 173: Osteoarthritis – Pipeline by Remedium Bio Inc, 2022
- Table 174: Osteoarthritis – Pipeline by ReqMed Co Ltd, 2022
- Table 175: Osteoarthritis – Pipeline by Ribomic Inc, 2022
- Table 176: Osteoarthritis – Pipeline by Rottapharm Biotech Srl, 2022
- Table 177: Osteoarthritis – Pipeline by Runjia (Suzhou) Pharmaceutical Technology Co Ltd, 2022
- Table 178: Osteoarthritis – Pipeline by Sclnow Biotechnology Co Ltd, 2022
- Table 179: Osteoarthritis – Pipeline by Seikagaku Corp, 2022
- Table 180: Osteoarthritis – Pipeline by Serene LLC, 2022
- Table 181: Osteoarthritis – Pipeline by Shandong Boan Biotechnology Co Ltd, 2022
- Table 182: Osteoarthritis – Pipeline by Shionogi & Co Ltd, 2022
- Table 183: Osteoarthritis – Pipeline by Simcere Pharmaceutical Group Ltd, 2022
- Table 184: Osteoarthritis – Pipeline by SL Bigen Co Ltd, 2022
- Table 185: Osteoarthritis – Pipeline by Steminent Biotherapeutics Inc, 2022
- Table 186: Osteoarthritis – Pipeline by Stempeutics Research Pvt Ltd, 2022
- Table 187: Osteoarthritis – Pipeline by Synartro AB, 2022
- Table 188: Osteoarthritis – Pipeline by Synerkine Pharma BV, 2022
- Table 189: Osteoarthritis – Pipeline by Synokem Pharmaceuticals Ltd, 2022
- Table 190: Osteoarthritis – Pipeline by Taiwan Bio Therapeutics Co Ltd, 2022
- Table 191: Osteoarthritis – Pipeline by Techfields Pharma Co Ltd, 2022
- Table 192: Osteoarthritis – Pipeline by TheraBioPharma Inc, 2022
- Table 193: Osteoarthritis – Pipeline by Traverse Biosciences Inc, 2022
- Table 194: Osteoarthritis – Pipeline by Tremeau Pharmaceuticals Inc, 2022
- Table 195: Osteoarthritis – Pipeline by Trialspark Inc, 2022
- Table 196: Osteoarthritis – Pipeline by Turn Biotechnologies Inc, 2022
- Table 197: Osteoarthritis – Pipeline by Unicocell Biomed Co Ltd, 2022
- Table 198: Osteoarthritis – Pipeline by Vitro Diagnostics Inc, 2022
- Table 199: Osteoarthritis – Pipeline by WEX Pharmaceuticals Inc, 2022
- Table 200: Osteoarthritis – Pipeline by WNT Scientific LLC, 2022
- Table 201: Osteoarthritis – Pipeline by Xalud Therapeutics Inc, 2022
- Table 202: Osteoarthritis – Pipeline by Xintela AB, 2022
- Table 203: Osteoarthritis – Pipeline by Yooyoung Pharm Co Ltd, 2022
- Table 204: Osteoarthritis – Pipeline by Zhejiang Yatai Pharmaceutical Co Ltd, 2022
- Table 205: Osteoarthritis – Pipeline by Zimmer Biomet Holdings Inc, 2022
- Table 206: Osteoarthritis – Dormant Projects, 2022
- Table 207: Osteoarthritis – Dormant Projects, 2022 (Contd..1)
- T
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.